188 related articles for article (PubMed ID: 20299133)
1. Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit.
Dizdar EA; Aydemir C; Erdeve O; Sari FN; Oguz S; Uras N; Dilmen U
J Hosp Infect; 2010 Aug; 75(4):292-4. PubMed ID: 20299133
[TBL] [Abstract][Full Text] [Related]
2. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC
J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712
[TBL] [Abstract][Full Text] [Related]
3. Outcome of the Respiratory Syncytial Virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study.
Alan S; Erdeve O; Cakir U; Akduman H; Zenciroglu A; Akcakus M; Tunc T; Gokmen Z; Ates C; Atasay B; Arsan S;
J Matern Fetal Neonatal Med; 2016; 29(13):2186-93. PubMed ID: 26365531
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model.
Saadah LM; Chedid FD; Sohail MR; Nazzal YM; Al Kaabi MR; Rahmani AY
Pharmacotherapy; 2014 Mar; 34(3):251-9. PubMed ID: 23897635
[TBL] [Abstract][Full Text] [Related]
5. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
Kurz H; Herbich K; Janata O; Sterniste W; Bauer K
J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241
[TBL] [Abstract][Full Text] [Related]
6. Use of palivizumab with other infection control measures to control respiratory syncytial virus outbreaks in neonatal care units.
Hammoud MS; Al-Taiar A; Raina A; Elsori D; Al-Qabandi S; Al-Essa M
J Trop Pediatr; 2016 Oct; 62(5):409-14. PubMed ID: 27118823
[TBL] [Abstract][Full Text] [Related]
7. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
Cox RA; Rao P; Brandon-Cox C
J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005
[TBL] [Abstract][Full Text] [Related]
8. Prevention of respiratory syncytial virus infection with palivizumab.
Thomas M; Bedford-Russell A; Sharland M
Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis against respiratory syncytial virus in premature infants. IMpact-RSV Study Group.
Top FH; Connor EM; Carlin DA
Lancet; 2000 Mar; 355(9208):1014. PubMed ID: 10768456
[No Abstract] [Full Text] [Related]
13. Medical and economic impact of a respiratory syncytial virus outbreak in a neonatal intensive care unit.
Halasa NB; Williams JV; Wilson GJ; Walsh WF; Schaffner W; Wright PF
Pediatr Infect Dis J; 2005 Dec; 24(12):1040-4. PubMed ID: 16371862
[TBL] [Abstract][Full Text] [Related]
14. Use of palivizumab and infection control measures to control an outbreak of respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time polymerase chain reaction.
O'Connell K; Boo TW; Keady D; Niriain U; O'Donovan D; Commane M; Faherty C; Cormican M
J Hosp Infect; 2011 Apr; 77(4):338-42. PubMed ID: 21330007
[TBL] [Abstract][Full Text] [Related]
15. Nosocomial Respiratory Viral Infection in the Neonatal Intensive Care Unit.
Vain NE
Am J Perinatol; 2020 Sep; 37(S 02):S22-S25. PubMed ID: 32898879
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
17. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
18. [Use of palivizumab in the prevention of syncytial virus respiratory infection].
Vagnarelli F; Magnani C; Vancini A; Bonacini G; Iori A; Mariani S; Attanasio M; Banchini G
Acta Biomed Ateneo Parmense; 2000; 71 Suppl 1():573-5. PubMed ID: 11424809
[TBL] [Abstract][Full Text] [Related]
19. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
Prais D; Schonfeld T; Amir J;
Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
[TBL] [Abstract][Full Text] [Related]
20. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).
Bollani L; Baraldi E; Chirico G; Dotta A; Lanari M; Del Vecchio A; Manzoni P; Boldrini A; Paolillo P; Di Fabio S; Orfeo L; Stronati M; Romagnoli C;
Ital J Pediatr; 2015 Dec; 41():97. PubMed ID: 26670908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
